147 related articles for article (PubMed ID: 24218035)
1. Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.
Penel N; Ray-Coquard I; Bal-Mahieu C; Chevreau C; Le Cesne A; Italiano A; Bompas E; Clisant S; Baldeyrou B; Lansiaux A; Robin YM; Bay JO; Piperno-Neumann S; Blay JY; Fournier C
Target Oncol; 2014 Sep; 9(3):273-7. PubMed ID: 24218035
[TBL] [Abstract][Full Text] [Related]
2. Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).
Lebellec L; Bertucci F; Tresch-Bruneel E; Bompas E; Toiron Y; Camoin L; Mir O; Laurence V; Clisant S; Decoupigny E; Blay JY; Goncalves A; Penel N
Oncotarget; 2016 Nov; 7(45):73984-73994. PubMed ID: 27659533
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial.
Lebellec L; Bertucci F; Tresch-Bruneel E; Ray-Coquard I; Le Cesne A; Bompas E; Blay JY; Italiano A; Mir O; Ryckewaert T; Toiron Y; Camoin L; Goncalves A; Penel N; Le Deley MC
BMC Cancer; 2018 Oct; 18(1):963. PubMed ID: 30305054
[TBL] [Abstract][Full Text] [Related]
4. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.
Tsuchiya K; Asahina Y; Matsuda S; Muraoka M; Nakata T; Suzuki Y; Tamaki N; Yasui Y; Suzuki S; Hosokawa T; Nishimura T; Ueda K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Izumi N
Cancer; 2014 Jan; 120(2):229-37. PubMed ID: 24122122
[TBL] [Abstract][Full Text] [Related]
5. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
Raut CP; Boucher Y; Duda DG; Morgan JA; Quek R; Ancukiewicz M; Lahdenranta J; Eder JP; Demetri GD; Jain RK
PLoS One; 2012; 7(2):e26331. PubMed ID: 22347360
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.
Cao G; Li X; Qin C; Li J
Med Sci Monit; 2015 Oct; 21():3144-51. PubMed ID: 26476711
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
Chevreau C; Le Cesne A; Ray-Coquard I; Italiano A; Cioffi A; Isambert N; Robin YM; Fournier C; Clisant S; Chaigneau L; Bay JO; Bompas E; Gauthier E; Blay JY; Penel N
Cancer; 2013 Jul; 119(14):2639-44. PubMed ID: 23589078
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Peña C; Lathia C; Shan M; Escudier B; Bukowski RM
Clin Cancer Res; 2010 Oct; 16(19):4853-63. PubMed ID: 20651059
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.
Bass MB; Sherman SI; Schlumberger MJ; Davis MT; Kivman L; Khoo HM; Notari KH; Peach M; Hei YJ; Patterson SD
J Clin Endocrinol Metab; 2010 Nov; 95(11):5018-27. PubMed ID: 20739388
[TBL] [Abstract][Full Text] [Related]
10. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
[TBL] [Abstract][Full Text] [Related]
11. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor.
Park MS; Ravi V; Araujo DM
Curr Opin Oncol; 2010 Jul; 22(4):351-5. PubMed ID: 20485168
[TBL] [Abstract][Full Text] [Related]
13. Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors.
Tamiya H; Kamo R; Kumei A; Yanagihara S; Ishii M; Kobayashi H
Clin Exp Dermatol; 2012 Oct; 37(7):749-52. PubMed ID: 22369131
[TBL] [Abstract][Full Text] [Related]
14. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
Mahalingam D; Malik L; Beeram M; Rodon J; Sankhala K; Mita A; Benjamin D; Ketchum N; Michalek J; Tolcher A; Wright J; Sarantopoulos J
Cancer Chemother Pharmacol; 2014 Jul; 74(1):77-84. PubMed ID: 24817603
[TBL] [Abstract][Full Text] [Related]
15. [Plasma Biomarkers as Predictive Factors for Advanced Hepatocellular Carcinoma with Sorafenib].
Shiozawa K; Watanabe M; Ikehara T; Matsukiyo Y; Kogame M; Shinohara M; Kikuchi Y; Igarashi Y; Sumino Y
Gan To Kagaku Ryoho; 2016 Jul; 43(7):863-7. PubMed ID: 27431630
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).
Ray-Coquard I; Italiano A; Bompas E; Le Cesne A; Robin YM; Chevreau C; Bay JO; Bousquet G; Piperno-Neumann S; Isambert N; Lemaitre L; Fournier C; Gauthier E; Collard O; Cupissol D; Clisant S; Blay JY; Penel N;
Oncologist; 2012; 17(2):260-6. PubMed ID: 22285963
[TBL] [Abstract][Full Text] [Related]
17. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.
Llovet JM; Peña CE; Lathia CD; Shan M; Meinhardt G; Bruix J;
Clin Cancer Res; 2012 Apr; 18(8):2290-300. PubMed ID: 22374331
[TBL] [Abstract][Full Text] [Related]
18. The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma.
Ho TH; Liu XD; Huang Y; Warneke CL; Johnson MM; Hoang A; Tamboli P; Wang F; Jonasch E
BMC Cancer; 2015 Apr; 15():304. PubMed ID: 25900027
[TBL] [Abstract][Full Text] [Related]
19. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management.
Faloppi L; Scartozzi M; Bianconi M; Svegliati Baroni G; Toniutto P; Giampieri R; Del Prete M; De Minicis S; Bitetto D; Loretelli C; D'Anzeo M; Benedetti A; Cascinu S
BMC Cancer; 2014 Feb; 14():110. PubMed ID: 24552144
[TBL] [Abstract][Full Text] [Related]
20. Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.
Azad N; Yu M; Davidson B; Choyke P; Chen CC; Wood BJ; Venkatesan A; Henning R; Calvo K; Minasian L; Edelman DC; Meltzer P; Steinberg SM; Annunziata CM; Kohn EC
Mol Cell Proteomics; 2013 Jun; 12(6):1621-31. PubMed ID: 23449826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
